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Background. S100B protein, previously proposed as a consolidated marker of brain damage in congenital heart disease (CHD)
newborns who underwent cardiac surgery and cardiopulmonary bypass (CPB), has been progressively abandoned due to S100B
CNS extra-source such as adipose tissue.Thepresent study investigatedCHDnewborns, if adipose tissue contributes significantly to
S100B serum levels.Methods.We conducted a prospective study in 26CHD infants, without preexisting neurological disorders, who
underwent cardiac surgery and CPB in whom blood samples for S100B and adiponectin (ADN) measurement were drawn at five
perioperative time-points. Results. S100B showed a significant increase from hospital admission up to 24 h after procedure reaching
its maximum peak (𝑃 < 0.01) during CPB and at the end of the surgical procedure. Moreover, ADN showed a flat pattern and no
significant differences (𝑃 > 0.05) have been found all along perioperative monitoring. ADN/S100B ratio pattern was identical to
S100B alone with the higher peak at the end of CPB and remained higher up to 24 h from surgery. Conclusions. The present study
provides evidence that, in CHD infants, S100B protein is not affected by an extra-source adipose tissue release as suggested by no
changes in circulating ADN concentrations.
1. Introduction
Advances in cardiothoracic surgical and anesthetic tech-
niques, including cardiopulmonary bypass (CPB), have sub-
stantially decreased mortality, expanding the horizon to
address functional neurologic and cardiac outcomes in long-
term survivors [1]. Acute neurocardiac morbidities in con-
genital heart disease (CHD) infants are well described and
interest in the functional status of survivors now stretches
beyond the newborn period to childhood, adolescence, and
adulthood [2]. Newborn heart surgery represents a period
of planned and deliberate hypoxia-ischemia (HI) injury,
which is the price to pay in the treatment or palliation
of CHD. To date, the possibility of detecting infants at
risk for mortality and morbidity is limited since clinical,
laboratory, and standard monitoring procedures may be
silent or unreliable [3].Thus, a practical and sensitive marker
able to offer physicians a useful tool for clinical is therefore
eagerly awaited.
In the last decade a brain constituent, namely, S100B
protein, has been proposed as a well-established marker
of brain damage and death [4–10], since elevated S100B
concentrations in different biological fluids have been found
in adults, infants, and fetuses at risk for brain damage [4–
15]. S100B is an acidic calcium-modulated protein of low
molecular weight, first identified by Moore as a protein
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fraction detectable in the central nervous system (CNS) in
glial and Schwann cells and in specific neuronal subpopu-
lations [16]. With regard to CHD infants who underwent
cardiac surgery and CPB, S100B has been shown to be
increased in the perioperative period [17, 18], to correlate
with different CPBphases [19] andwith increased cerebrovas-
cular resistance and brain damage [20]. However, protein’s
assessment in CHD infants for CPB monitoring has been
progressively abandoned on the basis of S100B extra CNS
site of concentrations including adipose tissue [21]. The issue
is still controversial and matter of debate. From one side, a
contamination originating by mediastinal tissues on S100B
releasing into systemic circulation has been suggested [22–
25]. From the other side, it has been shown that extracranial
sources of S100B do not affect serum levels and protein’s
diagnostic value in neurological diseases in intact subjects
[26]. In this setting, data in nonintact patients such aswithout
traumatic brain or bodily injury from accident or surgery are
still lacking.
Therefore, the objective of this current study was to
determine, in CHD newborns, if adipose tissue sources
contribute significantly to serum levels of S100B by means
of the longitudinal measurement of adiponectin (ADN), the
most abundant adipose-derived protein in humans [27] and
S100B at different perioperative time-points.
2. Materials and Methods
2.1. Patients. From March 2010 to September 2011, we
conducted an observational study in which 26 infants (15
males and 11 females) from 0 to 9 months of age (mean
30.4 months), without preexisting neurological disorders or
other comorbidities, admitted to our referral centers for the
correction of congenital heart defects (Table 1). Exclusion
criteria included need for inotropic support or mechanical
ventilation prior to surgery, recent cardiac arrest, and weight
of less than 2 kg.
Informed consent from parents was obtained before
patient inclusion in the study, which was approved by the
local human-investigation committee.
Blood samples were drawn at five predetermined time-
points in the preoperative period as follows: before the sur-
gical procedure (time 0, T0); during the surgical procedure
before CPB (time 1, T1); at the end of CPB (time 2, T2);
at the end of the surgical procedure (time 3, T3); 24 h
after the surgical procedure (time 4, T4). At these time-
points ADN levels and ADN/S100B ratio were measured.
Clinical parameters (peripheral temperature, nasopharyngeal
temperature, pump flow rate, mean blood pressure, and
arterial pH) were recorded at all sample times for the purpose
of monitoring the general pattern of the surgical procedure.
2.1.1. Anesthetic Technique. After premedication with mida-
zolam 0.5mg/Kg bw (rectal/intramuscular), induction was
achieved with oxygen and 3% sevofluorane administered
via mask (single breath induction), followed by intravenous
sufentanil 1 (g/Kg bw) and vecuronium (0.15mg/Kg bw).
Maintenance was achieved with 3% sevofluorane (except
Table 1: General characteristics and perioperative data in the infants
admitted into the study. Data are given as mean ± SD.
Parameters
Age (months) 41.6 ± 30.4
Sex (male/female) 15/11
Weight (Kg) 11.5 ± 4.7
Type of surgery
Great artery transposition (no) 4
Ventricular septal defect (no) 5
Total anomalous pulmonary vein connection (no) 4
Tetralogy of fallot (no) 2
Double outlet right ventricle (no) 3
Complete A-V canal defect (no) 2
Atrial septal defect (no) 6
CPB duration (min) (no) 89.9 ± 43.4
Cross clamp duration (min) 45.1 ± 32.2
Temperature in CPB (∘C) median 31.8 ± 3.5
MUF (no) 20
AV: atrioventricular; CPB: cardiopulmonary bypass; and MUF: modified
ultrafiltration.
during CPB) and with additional doses of sufentanil
(0.5 g/Kg bw) and vecuronium (0.1mg/Kg bw) every 30–
40min. During CPB, in the absence of sevofluorane, addi-
tional midazolam at 0.2mg/Kg bw dosage was given. Sufen-
tanil infusion at 0.25 g/Kg bw was continued in the intensive
care unit for sedation.
2.1.2. Cardiopulmonary Bypass Management. CPBwas estab-
lished after systemic heparinization (3mg/Kg bw) by stan-
dard single stage aortic and bicaval cannulation and was
maintained via nonpulsatile pump flow with a membrane
oxygenator (Dideco Laboratories, Modena, Italy). Flow
velocity was kept at 120–150mL/Kg bw and mean arterial
blood pressure at 45mmHg; hypothermia was attained by
core and surface cooling. Mean CPB duration time was 90 ±
43min; mean rewarming time was 15 ± 8min (mean ± SD),
calculated from the final temperature during hypothermic
circulatory arrest to 36.5∘C. The minimum temperature
reached was 27.2∘C. The pump priming solution was com-
posed of electrolyte solutions (Normosol-R 250 to 650mL,
Abbott Hospital Products, Abbott Park, IL, USA or Plasma-
Lyte A, Travenol Laboratories, Inc., Deerfield, IL, USA),
albumin (25%), heparin 1000 to 5000 units in the total
solution, sodiumbicarbonate (25–30mEq/L), and packed red
blood cells or fresh frozen plasma. A standard circuit prime
total volume was used, according to body-weight varying
from 400mL (bw < 4.5 Kg) to 600mL (bw > 4.5 Kg and bw <
7.5 kg) and to 700mL (bw > 7.7 kg). Packed red blood cells
(200 to 500mL) were transfused as necessary to maintain
a hematocrit level above 30% during CPB [26]. Protamine
(1mg for each mg of heparin) was administered at the end
of CPB.
The 𝛼-stat regimen was used, and the PaCO
2
was main-
tained between 35 and 40mmHg, without mathematical
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correction for the effects of the temperature, by varying the
membrane oxygenator gas flow.
2.1.3. Adiponectin Measurement. Serum ADN concentra-
tions were determined by an enzyme-linked immunosorbent
assay (Human Adiponectin ELISA, EZHADP-61 K; Linco
Research). Sensitivity limit for this assay is 0.78 ng/mL for
Human Adiponectin (20 𝜇L sample size). The appropriate
range of the assay is 1.56 to 200 ng/mL Human Adiponectin
(20𝜇L sample size). The results were evaluated according to
ng/mL.
2.1.4. S100B Measurement. Samples for S100B measurements
at the seven monitoring time-points were drawn from a
catheter inserted in the jugular vein. Heparin-treated blood
samples were immediately centrifuged at 900 g for 10min and
the supernatants were stored at −70∘C before measurement.
The S100B protein concentration wasmeasured in all samples
using a commercially available two-site immunoradiomet-
ric assay kit (Sangtec 100; AD Sangtec Medical, Bromma,
Sweden) specific to the 𝛽-subunit of the protein, which is
known to be present mostly (80–96%) in the human brain
[28]. Each measurement was performed in duplicate and the
mean values are reported. The limit of sensitivity of the assay
was 0.02 𝜇g/L. The precision (CV) was <10%.
2.1.5. Neurological Follow-Up. Neurological development
was assessed by physical examination, preoperatively and on
the 7th postoperative day, based on Amiel-Tison’s criteria
[29]. In particular, resistance against passive movements,
visual pursuit, reaching and grasping, and responses to visual
and acoustic stimuli were tested by the same examiner, who
did not know of the subjects’ presurgical condition.
2.2. Statistical Analysis. ADN and S100B plasma concen-
trations are expressed as median and 5–95% coefficient
intervals (CI). Comparisons at the differentmonitoring time-
points were analyzed by Kruskal-Wallis one-way ANOVA.
Linear regression analysis was used for correlation between
ADN and S100B and various parameters (CPB, cooling, and
rewarming duration; body core temperature; arterial blood
pH, arterial oxygen and carbon dioxide partial pressures, and
base excess; andmean arterial blood pressure and heart rate).
Statistical significance was set at 𝑃 < 0.05.
3. Results
In Table 1 patients’ characteristics are reported. Clinical, lab-
oratory, and standard monitoring parameters recorded at the
predetermined time-points remained within the reference
limits and therefore were not different (𝑃 > 0.05; for all)
in all infants. Intraoperative parameters such as CPB, cross-
clamping, cooling, and rewarming durations were within
reference ranges and no perioperative complications have
been shown. No complications in the postoperative period
have been reported and no overt neurological disease was
detected at discharge from hospital.
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Figure 1: Adiponectin (ADN) (ng/mL) blood concentrations
expressed as median and coefficient intervals (CI
5–95%) at different
monitoring time-points (before the surgical procedure (T0); during
the surgical procedure after sternotomy before CPB (T1); at the end
CPB (T2); at the end of the surgical procedure (T3); and at 24 h after
the surgical procedure (time 4, T4)).
ADN was measurable in all samples collected. ADN
pattern at different monitoring time-points showed a flat
trend and therefore no significant differences (𝑃 > 0.05, for
all) have been found all along perioperative monitoring up to
24 h from surgery (T0–T4) (Figure 1).
S100B was measurable in all samples collected. S100B
pattern at differentmonitoring time-points was characterized
by a protein’s significant increase (𝑃 < 0.01, for all), reaching
its highest peak at the end of CPB and remaining stable up to
24 h from surgery (Figure 2(a)).
Linear regression analysis showed no significant corre-
lations (𝑃 > 0.05, for all) between ADN and S100B at
all monitoring time-points (T0–T4) and between ADN and
CPB (𝑟 = 0.08; 𝑃 = 0.73) and cross clamp (𝑟 = 0.05; 𝑃 =
0.82) durations. Conversely, S100B significantly correlated
with CPB (𝑟 = 0.53; 𝑃 = 0.003) and at cross clamp (𝑟 = 0.65;
𝑃 < 0.01) durations.
ADN/S100B ratio pattern was characterized by a signif-
icant increase (𝑃 < 0.01) from T0 to T3 reaching its dip at
T2 and returning at T4 at preoperative levels. No significant
correlations (𝑃 > 0.05, for all) between ADN/S100B ratio
and CPB (𝑟 = 0.12; 𝑃 = 0.56) and cross clamp (𝑅 = 0.19;
𝑃 = 0.35) duration have been found (Figure 2(b)).
4. Discussion
Despite recent advances in cardiac surgery and CPBmanage-
ment, the possibility of detecting infants at risk for neonatal
mortality and morbidity is still faraway due to limitations
in the standard monitoring procedures currently performed
[1, 2]. In this setting, brain biomarkers previously suggested
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Figure 2: (a) S100B (𝜇g/L) blood concentrations expressed as median and coefficient intervals (CI
5–95%) at different monitoring time-points
(before the surgical procedure (T0); during the surgical procedure after sternotomy before CPB (T1); at the end CPB (T2); at the end of the
surgical procedure (T3) and at 24 h after the surgical procedure (time 4, T4)). ∗𝑃 < 0.01 versus T0. (b) S100B (𝜇g/L) and adiponectin (ADN)
(ng/mL) blood concentrations expressed as median and coefficient intervals (CI
5–95%) at different monitoring time-points (before the surgical
procedure (T0); during the surgical procedure after sternotomy before CPB (T1); at the end CPB (T2); at the end of the surgical procedure
(T3); and at 24 h after the surgical procedure (time 4, T4)). ∗𝑃 < 0.01 versus T0.
as promising tools disappointed expectations and, to date,
a trustable biomarker of brain damage in the perioperative
period is still eagerly awaited. This holds for S100B protein,
first reported as a useful tool and later on abandoned for
brain monitoring of CHD adults and children [18–21]. The
explanations are still controversial and debated although the
main resides in a contamination by protein’ extrasources such
as adipose tissue [22–25].
The present study provides evidence that, in CHD infants,
S100B protein is not affected by an extrasource adipose
tissue release as suggested by no changes in circulating ADN
concentrations. Furthermore, the ADN/S100B ratio pattern
was superimposable to S100B alone all along the perioperative
period.
The finding of ADN trend in the perioperative period
is not surprising and fits, in part, previous observations in
pediatric patients where decreased ADN levels have been
reported [27]. The discrepancies are several and reside in the
number, timing, and the length of themonitoring time-points
and in the different CPBmanagement (mild versus moderate
hypothermia). In this setting, hypothermia is known to acti-
vate an exaggerated release of proinflammatory cytokines and
of endogenous cortisol that may be responsible of decreased
ADN transcription and blood levels [27, 30, 31]. Anyway,
further investigations comparing ADN pattern under differ-
ent CPB management such as mild versus moderate/deep
hypothermia are so justified.
The finding of increased S100B levels and flat ADN/S100B
ratio enforces the debating issue on the protein’ pros and cons
as brain stress/damage marker in CHD patients. From one
hand, the absence of any interference in circulating S100B
in the perioperative period is in agreement with previous
observations, both in adults and children, reporting no
compromise on the diagnostic value of S100B in neurological
diseases in intact subjects (without traumatic brain or bodily
injury from accident or surgery) [26]. These findings are
also consistent with the usefulness of the protein in brain
monitoring of CHD infants [18–20]. On the other hand,
the discrepancy with previous observations warrants further
consideration in terms of contamination following invasive
procedures during CPB. This refers to CPB standard proce-
dures, known to increase mediastinum release of the pro-
tein, as pericardial suction blood re-/autotransfusion, zero-
balanced ultra-filtration, and pericardial blood processing
with cell-saving devices [22–25, 32–34]. The high S100B
levels at the site of reinfusion is per se of limited relevance
because of the known mediastinum site of concentration of
the protein. In fact, once S100B was measured in systemic
circulation, after reinfusion procedures, its concentration
did not appear to be affected by mediastinum source [35].
The main explanations reside in lowest S100B extrasources’
concentrations when compared with the total amount of the
protein in the CNS [36]. Although, there are no observa-
tions in pediatric and postnatal periods in whom protein
distribution in CNS and other tissues can differ or not from
adults [37], in the latter (estimated for a 70Kg man) the
absolute amount of S100B in the tissue (calculated in micro-
grams) showed the highest protein’s concentration in brain
(538.000𝜇g: 90.9%) followed by muscles (42.000𝜇g: 7.1%),
adipose tissue (10.500 𝜇g: 1.77%), heart (1.000𝜇g: 0.2%),
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and liver (200𝜇g: 0.03%) [36]. Taken together, the possibility
that adipose tissue could constitute a significant source of
contamination affecting S100B diagnostic value seems to be
fairly remote.
Among different S100B sites of contamination car-
diac tissue extrasource deserves further consideration [36].
In particular (i) in rat model of myocardial infarction it has
been shown that S100B may play a dual role in cardiomy-
ocytes survival or death (i.e., necrosis and apoptosis) through
a RAGE-dependentmechanism, and (ii) S100B, once released
from damagedmyocytes, with consequent leakage of the pro-
tein into the systemic circulation, is approximately 1000-fold
less than the amount of protein required to induce apoptosis
[38]. Indeed, local high S100B concentration was detected
only at the site of myocardial infarction and, finally, (iii) in
humans, cardiac tissue contamination on S100B has been
justified by a correlation between troponin I and S100B [23]
although a hypoxia mediated effect could be reasonably the
main explanation of the increase in circulating biomarkers’
levels [3, 4]. Altogether, bearing in mind the extremely low
protein’ concentrations in cardiac tissue the present findings
suggest that the possibility of a cardiac tissue extrasource
contamination on circulating S100B levels argue against this
hypothesis. Conversely, it is reasonable to suppose that the
upregulation of S100B protein is a consequence of hypoxia
itself, instead of dead cells belonging to the necrosis/apoptosis
area. To this regard, it has been demonstrated both in humans
and in sheep model that acute hypoxemia is able to induce a
significant increase in S100B release within 15 minute form
insult in absence of any CNS damage [39]. This is of great
relative interest to this contest because, as shown in our series,
it is possible to argue that H-I insult occurring during CPB
phase may trigger protein’s release due to “multiorgan” stress
of whom CNS constitutes the majority of the total protein’s
amount [3, 4, 36]. In this regard, further studies aimed at
investigating potential confounding factors such as S100A1
and RAGE and the S100A1B dimer interactions in the cascade
of events leading to cell death and apoptosis are still needed.
In conclusion, our results showing, in nonintact patients,
that S100B protein is not affected by an extrasource adipose
tissue release during the perioperative period open up further
studies, in wider populations, aimed at confirming protein’s
role of early marker of hypoxia and CNS stress/damage in
CHD children.
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